Category: News

DRI Healthcare Trust Reports Third Quarter 2024 Results

53% adjusted EBITDA growth over prior year period shows strong focus on cash generation Recent acquisitions and credit facility expansion highlight growth under new leadership  TORONTO, Nov. 6, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the quarter ended September 30, 2024. The Trust’s third […]

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals

– First pre-approval royalty acquisition and first equity investment highlight evolving investment strategy – – Up to US$184 million investment brings capital deployment to over US$1 billion since IPO – – Long-term asset in new therapeutic area further increases portfolio duration and diversification – TORONTO, Nov. 4, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: […]

DRI Healthcare Trust Announces Upsized US$631.6 Million Credit Facilities

– Enhances deployment capacity without increasing leverage parameters – – Sufficient funding to achieve 2025 deployment target – – Marginal decrease in interest rate and standby fees – TORONTO, Nov. 1, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life […]

DRI Healthcare Trust Announces Acquisition of Payment Streams based on the Cas9 Gene-Editing Technology for CASGEVY® (exagamglogene autotemcel)

– Transaction adds another innovative rare disease therapy to the DHT portfolio – – Novel deal structure offers predictable annual cash flows as well as potential additional annual sales-based milestones and a one-time contingent payment – TORONTO, Oct. 3, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") today announced that a wholly […]

DRI Capital Inc. Updates Executive Changes

TORONTO, September 27, 2024  – DRI Healthcare Trust recently announced that its investigation into consulting and other expenses submitted had substantially concluded. DRI did not find Chris Anastasopoulos to have submitted any inappropriate consulting or other expenses. Mr. Anastasopoulos has since advised DRI Capital that he has decided to resign to pursue other opportunities. He will remain […]

DRI Healthcare Trust Reports Second Quarter 2024 Results

– Highest Normalized Total Cash Receipts in a single quarter since IPO, excluding milestones – – Trust internal investigation substantially complete with no impact to cash royalty receipts –  – New executive leadership in place and in-depth review of governance practices underway – TORONTO, Aug. 6, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or […]

DRI Healthcare Trust and DRI Capital Inc. Announce Executive Changes

TORONTO, July 8, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the “Trust”) and DRI Capital Inc. (“DRI Healthcare”), the manager of the Trust, today announced changes to their respective senior executive teams.  The Board of Trustees of the Trust (the “Board”) has appointed Gary Collins as the interim CEO of the Trust in addition to his role as Chair […]

DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency

– Transaction pushes total committed capital to over US$1 billion since IPO – – Second Xenpozyme royalty increases exposure to rare diseases – – Long-term asset further increases portfolio duration – TORONTO, July 2, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in […]